Back to Search
Start Over
Overcoming resistance to immunotherapy by teaching old drugs new tricks.
- Source :
-
Molecular & cellular oncology [Mol Cell Oncol] 2020 Aug 12; Vol. 7 (5), pp. 1801088. Date of Electronic Publication: 2020 Aug 12 (Print Publication: 2020). - Publication Year :
- 2020
-
Abstract
- Cancer stem cells (CSCs) underlie resistance to therapy. Cancer develops only in the context of failing immunosurveillance, and stem cells occupy immune privileged microenvironments. Recent evidence demonstrates that CSCs borrow immune privilege from their normal counterparts. However, low doses of doxorubicin can target CSCs by restoring anticancer immunity.<br /> (© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.)
Details
- Language :
- English
- ISSN :
- 2372-3556
- Volume :
- 7
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Molecular & cellular oncology
- Publication Type :
- Academic Journal
- Accession number :
- 32944648
- Full Text :
- https://doi.org/10.1080/23723556.2020.1801088